

# CUMULATIVE INDEX 1994

## Volume 14

---

March	BLOOD CULTURES, pages 1-202
June	HIV/AIDS, pages 203-450
September	ALTERNATE-SITE LABORATORY TESTING, pages 451-676
December	THROMBOSIS AND HEMOSTASIS: PART I, pages 677-869

---

Note: Page numbers of article titles are in **boldface** type

- A77003 (protease inhibitor), in HIV infection, 379
- Abbott MS-2 system, for antibiotic susceptibility testing, 177
- for rapid microbial identification, 187
- Abortion, saline-induced, disseminated intravascular coagulation in, 732
- spontaneous, from lupus anticoagulants, 797
- Abuscreen OnTrak, for urine screening, 487
- Accreditation, in alternate-site testing, 605-622
- College of American Pathologists, 606-607
- checklist for, 475-480, 484, 608-616
- in multihospital systems, 504-505
- Joint Commission on Accreditation of Healthcare Organizations, 607, 616-622
- AccuProbe test, in rapid microorganism detection, 191
- Acidosis, in disseminated intravascular coagulation, 733, 739
- ACL instrument, for coagulation evaluation, 717-718
- Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.
- Acridinium ester probe, in HIV detection, 317
- Actinobacillus actinomycetemcomitans*, blood culture of, 124
- Activated clotting time, in heparin therapy monitoring, 827
- Activated partial thromboplastin time, high phospholipid, in lupus anticoagulants, 799
- in cirrhosis, 772
- in disseminated intravascular coagulation, 743
- in factor VIII inhibitor disorders, 804
- in heparin therapy monitoring, 827-830
- in hirudin therapy monitoring, 833-834
- in lupus anticoagulants, 798
- measurement of, automated instruments for, 710-715
- phosphatidylserine liposome, in lupus anticoagulants, 799
- Adenoviruses, in gene therapy, for HIV infection, 380-381
- Agar, for blood cultures, 55
- Agar dilution method, for antibiotic susceptibility testing, 175
- Agar slant, in biphasic blood cultures, 136-137
- Agarose gel method, for factor VIII inhibitor screening, 805
- Agglutination tests, for rapid microbial identification, 187-188
- Aging, lead poisoning in, 438-439
- Agnogenic myeloid metaplasia, disseminated intravascular coagulation in, 733
- AIDS. See *Human immunodeficiency virus infection*.
- Air, lead release into, 425
- testing of, for lead, 660
- Alcohol ingestion, lead poisoning in, 438
- Alkalosis, disseminated intravascular coagulation in, 733
- Alpha-2-antiplasmin, action of, 694

Alpha-2-antiplasmin (*Continued*)

deficiency of, in cirrhosis, 772  
in disseminated intravascular coagulation, 747-748

Alternate-site testing. *See also Bedside testing.*

accreditation in, 475-480, 484, **605-622**  
in multihospital system, 504-505  
advantages of, 553, 628  
background of, **451-458**  
historical aspects of, 451-453  
nomenclature, 453-456  
professional organization position, 456-458  
biosensor technology for, **459-471**  
calibration in, 593  
central laboratory representative in, 572-573  
clinician vs. laboratorian view of, 452  
common tests performed in, 587  
communication in, **559-567**  
competency testing requirements in, 597  
consolidation in multihospital systems, **493-524**  
accreditation in, 504-505  
chief of pathology and laboratory medicine role in, 499  
CLIA impact on, 507-508  
committee for, 499, 510-513  
coordinator in, 499-501  
costs of, regulation-related, 506  
example of, 501-503  
glucose testing device guidelines, 513-516  
history of, 494-495  
patient outcome and, 505-506  
personnel for, 517-518  
proficiency testing in, 503-504  
rationale for, 495-498  
regulation enforcement in, 505  
sites included in, 498  
test management in, 516-517  
Veterans Health Administration procedures for, 508-524  
data base design for, 563  
definition of, 454-455, 624  
disadvantages of, 553, 628-629  
domains of, 454-456  
economic aspects of, 453, 570-571  
consolidation in multihospital systems, 506  
in glucose determination, 485-486  
quality control and, 541-542  
errors in, detection of, 495-497  
potential for, 543-545, 550  
evolution of, 570-574  
growth of, 625-626  
historical aspects of, 451-453  
in mobile laboratory, 572  
in patient-centered units, **525-538**, 573

in satellite laboratory, 571-572  
in vivo, 456, 468-469, 573-574  
instrument maintenance in, 595-596  
interactive multimedia communication networks for, **559-567**  
nomenclature problems in, 453-456  
patient outcome and, 505-506  
performance of, survey on, 640-643  
personnel for, **569-604**, 630-636  
central laboratory representative in, 572-573  
certification/credentialing of, 585-586  
clinical consultant, 584-585  
competency testing of, 597  
continuing education of, 599-601  
education of, 577-578, 597-601  
in multihospital systems, 517-518  
in patient-centered unit, 526, 528-529, 535-536, 573  
interest of, 576  
medical director, 584-585  
proficiency testing in. *See Proficiency testing.*  
regulations on, 575, 583-585  
requirements for, 569-575  
site-specific considerations in, 586-588  
technical consultant, 584-585  
time available to, 576-577  
training of. *See Training, for alternate-site testing.*  
vs. central laboratory personnel, 574-575  
physician-performed microscopy, 583-584  
politicoeconomic aspects of, 453  
professional organization position on, 456-458  
proficiency testing in, 595  
in multihospital system, 503-504  
survey on, 637-640  
quality control/assurance in, **539-557**  
survey on, 633, 637  
training for, 590-594  
settings for, 498, 561, 571  
survey on, **623-645**  
design of, 624  
results of, 625-629  
advantages, 628  
disadvantages, 628-629  
growth of, 625-626  
hospital size and, 625  
length of stay and, 626  
perceived performance, 640-643  
persons executing tests, 630-636  
proficiency, 637-640  
quality control practices, 633, 637  
time available for, 576-577  
training for. *See Training, for alternate-site testing.*  
vs. hospital size, 625

- vs. length of stay, 626
  - vs. monitoring, 588
  - Alveolar macrophages, in HIV-specific cytotoxic T lymphocyte detection, 272-273
  - Ambulance, biosensor testing in, 462-463
  - Aminoglycosides, in HIV infection, 376
  - Aminolevulinic acid, measurement of, in lead poisoning, 662
  - Aminolevulinic acid dehydrase, inhibition of, in lead poisoning, 649-650
  - Aminolevulinic acid synthetase, inhibition of, in lead poisoning, 649-650
  - Amniotic fluid embolism, disseminated intravascular coagulation in, 731
  - Amplification, of DNA. *See Polymerase chain reaction.*
  - Anaerobic bacteremia, **107-117**
    - blood cultures in, 25, 110-114
    - incidence of, 107-108
    - microbiology of, 108-110
  - Analysts, for alternate-site testing. *See Alternate-site testing, personnel for.*
  - Analyzer, portable, 464-465
  - Ancillary testing. *See Alternate-site testing.*
  - Anemia, in lead poisoning, 649-650
  - Anergy, in HIV infection, 229
  - Antibiotic(s), removal of, from blood cultures, 40, 75, 140-141
  - Antibiotic susceptibility testing, **171-179**
    - agar dilution method for, 175
    - agents for, 171-172
    - automated, 176-178
    - direct, 173
    - disk diffusion method for, 173, 175
    - manual methods for, 173-175
    - standardized, 172-173
  - Antibodies. *See also Circulating anticoagulants.*
    - in gene therapy, for HIV infection, 381-382
    - in HIV infection, serologic assays for. *See under Serologic assays.*
    - to factor IX, laboratory assessment of, 807
    - to factor VIII, laboratory assessment of, 803-807
  - Anticoagulants (circulating). *See Circulating anticoagulants.*
  - Anticoagulants (pharmacologic), in blood cultures, 74-75
    - in samples, for reverse transcriptase-polymerase chain reaction, 338
  - therapy with, in disseminated intravascular coagulation, 754-755, 758
    - monitoring of, **813-823, 825-846**
      - glycosaminoglycans, 831, 833
      - heparin, 826-835
      - hirudins, 835-836
      - historical background of, 813-815
      - international normalized ratios in, 814-815, 817-821
      - NO donors, 840
      - oral, **813-823**
      - pentasaccharides, 832
      - platelet function inhibitors, 838-839
      - reference preparations for, 815-817
      - thrombin-inhibiting peptides, 836
      - vitamin K antagonists, 837
  - Antifibrinolytic agents, in disseminated intravascular coagulation, 756-757
    - in liver transplantation, 775
  - Antiphospholipid antibodies, laboratory assessment of, 799-801
  - Antiplatelet agents, in disseminated intravascular coagulation, 755, 758
    - therapy with, monitoring of, 838-839
  - Antiretroviral drugs, **367-391**
    - affecting HIV replication, 368-380
      - at CD4 receptor binding step, 370-371
      - at cellular penetration step, 372
      - at host genome penetration step, 372
      - at transcription and translation stage, 373-379
      - at viral assembly stage, 379-382
      - at viral release stage, 379-382
    - efficacy of, monitoring of, 413-414
    - polymerase chain reaction in, 327-328, 344-346
  - HIV burden response to, 305-308
  - HIV resistance to, **393-422**
    - as pathogenic factor, 408-410
    - biochemical bases of, 404-407
    - efficacy monitoring in, 413-414
    - genetic factors in, 395-399
    - in combination therapy, 400-404
    - monitoring for, 410-413
    - mutations in, 400-404
    - replication dynamics and, 394-395
    - reverse transcriptase structure and, 404-407
- Antisense oligonucleotides, in HIV infection, 373-374
- Antisense RNA, in HIV infection, 374
- Antisepsis, skin, in blood culture sample collection, 60-61
- Antithrombin, deficiency of, in cirrhosis, 772
  - heparin affinity to, 826
  - in coagulation regulation, 698-699
  - measurement of, chromogenic assay in, 715
  - in disseminated intravascular coagulation, 746
  - therapeutic, in disseminated intravascular coagulation, 755
- API 20E system, for rapid microbial identification, 186-187
- Apoptosis, of T lymphocytes, in HIV infection, 229-230

- Aprosulate, therapy with, monitoring of, 831
- Arachidonic acid metabolites, in platelet function, 686-687
- Aspergillus*, blood culture of, 93
- Aspirin, in disseminated intravascular coagulation, 758
- therapy with, monitoring of, 838
- Ateviridine, HIV resistance to, 397, 399
- Atherosclerotic plaque, in endothelial injury, 679
- Atomic absorption spectrometry, in lead measurement, 661
- Autobac antibiotic susceptibility testing system, 177-178
- Automation, of antibiotic susceptibility testing, 176-178
- of blood cultures, 65-66, 149-169. See also specific system, e.g., BACTEC systems.
- of coagulation laboratory, 709-728
- instrumentation for, chromogenic assay, 715-720
- clot-based, 711-715
- immunologic assay, 722-725
- platelet, 720-722
- quality control of, 710-711, 725-726
- of microbial identification, 186-187
- 12-Azidodecanoic acid, in HIV infection, 377
- AZT. See Zidovudine (AZT).
- BacT/Alert blood culture system, 161-163
- in anaerobic bacteremia, 114
- in brucellosis, 121-122
- BACTEC systems, 150-156, 163-164
- advantages of, 153
- antibiotic removal device for, 140-141
- continuous-monitoring, 157-161, 163-164
- disadvantages of, 153
- for pediatric patients, 23-25
- in anaerobic bacteremia, 112-114
- in brucellosis, 120-122
- in *Campylobacter* bacteremia, 123
- in fungemia, 85-86, 88
- in mycobacteremia, 101-102
- in mycoplasmaemia, 126
- in vitamin B<sub>6</sub>-dependent streptococci infection, 127
- nonradiometric, 154-156
- Bacteremia. See also specific organism.
- anaerobic. See *Anaerobic bacteremia*.
- breakthrough, 10
- catheter-related, blood cultures in, 51-58
- continuous, 10
- definition of, 2-3
- epidemiology of, 11-13
- intermittent, 10
- microorganisms in, 10-11, 13
- in immunodeficiency, 33
- in pediatric patients, 17-20
- mortality in, 13-15
- nosocomial, in pediatric patients, 30
- polymicrobial, 10
- sources of, 13
- transient, 9-10
- unimicrobial, 10
- Bacteroides*, blood culture of, 108-109
- Bac-T-Screen instrument, for rapid microbial identification, 187
- Beckman CX3 analyzer, 465
- Beckman instruments, for coagulation evaluation, 725
- Bedside testing, 473-491, 627
- biosensors for, 460-462
- blood gases, 487
- casual, 573
- coagulation status, 486
- definition of, 456
- drugs of abuse, 487
- glucose, 474-480
- accuracy of, 477-479
- cost of, 485-486
- devices for, 474-476
- error consequences in, 479-480
- precision of, 476-477
- program components for, 481-485
- quality assurance in, 481-485
- regulation of, 480
- hemoglobin, 487
- multichannel analyzer for, 486-487
- perceived performance of, 643
- personnel for, 632
- proficiency, 639
- program components for, 481-485
- quality assurance in, 481-485
- regulation of, 480
- revenues from, 636
- Benzodiazepines, in HIV infection, 375-376
- Bethesda method, for factor VIII inhibitor assessment, 805-806
- Bile solubility test, for microorganism identification, in blood cultures, 185-186
- Bio Data instruments, for platelet function evaluation, 721
- BioArgos system, 114, 156-157
- Biochemical tests, for microorganism identification, in blood cultures, 184-187
- bioMerieux system, for antibiotic susceptibility testing, 176
- for blood cultures, 165
- for rapid microbial identification, 186-187
- Biosensors, 459-471
- analytes detected by, 461
- clinical settings for, 462-463

- communication system for, 462  
 components of, 460-461  
 definitions of, 460  
 electrochemical, 464-465  
 in bedside testing, 460-462  
   advantages of, 463-464  
 in blood gas monitoring, 466-468  
 in continuous monitoring, in vivo, 468-469  
   noninvasive, 466-468  
 in glucose monitoring, 469  
 in near-infrared spectroscopy, 467-468  
 in pulse oximetry, 467  
 performance criteria for, 462  
 prerequisites for, 461-462  
 specimen size for, 461-462  
 test result reporting time for, 462-463  
 transcutaneous, 466-467
- Bio-Tek Instruments, for coagulation evaluation, 725
- Blastomyces dermatitidis*, blood culture of, 93
- Bleeding, from factor VIII inhibitors, 803-804  
   treatment of, 807  
 from lupus anticoagulants, 798  
 in disseminated intravascular coagulation, 730  
   in diagnosis, 739  
   mechanisms of, 738  
 in heparin therapy, 833-834  
 in liver disease, 770  
 in liver resection, 776  
 in liver transplantation, from preexisting coagulopathy, 775  
 in vitamin K antagonist therapy, 837  
 in von Willebrand's disease, 781-783  
   acquired, 790-791
- Bleeding time, in von Willebrand's disease, 789
- Blood, lead measurement in, 656  
   methods for, 660-662  
   sample collection for, 658-659  
   lead poisoning effects on, 649-650
- Blood cultures, 1-7  
   agitation of, 74  
   anaerobic, 107-117  
     in pediatric patients, 25  
   antibiotic removal from, 75, 140-141  
     in immunocompromised patients, 40  
   antibiotic susceptibility testing in, 171-179  
   anticoagulants for, 74-75  
   automated, 65-66, 149-169. See also specific system, e.g., BACTEC systems.  
     in fungemia, 86, 88-89, 91  
 BacT/Alert system for, 161-163  
   in anaerobic infection, 114  
   in brucellosis, 121-122  
 BACTEC systems for. See BACTEC systems.
- BioArgos system for, 114, 156-157  
 biochemical detection methods for, 184-187  
 bioMerieux Vital system for, 165  
 biphasic, 136-139  
   in anaerobic infection, 112  
   in fungemia, 85-86  
 blood-to-broth ratio in, 72-73  
 broth displacement system in, 139-140  
 broth-based systems for, 133-136  
 chromatographic detection methods for, 191  
 clinical importance of, 3-4, 9-16  
 comparative studies of, critical factors in, 3-6  
 contamination of, 11  
   in fungal cultures, 91-92  
 continuous-monitoring systems for, 157-166  
 cost considerations in, in pediatric patients, 27  
 definition of, 2  
 Difco ESP system for, 164-165  
 direct microscopy in, in catheter-related infections, 53  
   in immunocompromised patients, 40  
   in mycobacteremia, 100-101  
   in pediatric patients, 26  
 false-positive, 1-3, 42-43  
 fluorescent stains for, in immunocompromised patients, 40  
 general principles of, 69-82  
 head space atmosphere in, 73  
 immunologic detection methods for, 187-191  
 in brucellosis, 120-123  
 in *Campylobacter* infection, 123-124  
 in catheter-related infections, 51-58  
 in fungemia, 83-97  
   catheter-related, 51-58  
   in immunocompromised patients, 37-38  
 in HACEK bacterial infection, 124  
 in immunocompromised patients, 31-49  
 in legionellosis, 124-125  
 in *Malassezia* infections, 24-25  
 in vitamin B<sub>6</sub>-dependent streptococcal infections, 127  
 incubation of, 4-5  
   atmosphere for, 111  
   broth-based, 136  
   duration of, 65, 73  
   anaerobic, 111  
   in immunocompromised patients, 41  
   in pediatric patients, 25-26  
   in fungemia, 89-90  
   temperature for, 73-74  
 interpretation of, in immunocompromised patients, 42-43

Blood cultures (*Continued*)

- isolator system for, 24, 142-144
  - in anaerobic bacteremia, 112-113
- laboratory issues in, in pediatric patients, 23-26
- lysis-centrifugation system in. See *Lysis-centrifugation system*.
- manual, 133-147
  - in brucellosis, 122
  - media for. See under *Culture media*.
  - MicroScan system for, 165-166
  - mycobacterial, 99-105
    - in immunocompromised patients, 38-39
  - mycoplasmal, 125-126
  - negative, in immunocompromised patients, 41-42
  - nucleic acids detection methods in, 191
  - number of, 69-70
    - in immunocompromised patients, 35
    - in pediatric patients, 21-22
  - of fastidious microorganisms, 119-131
  - on agar, 55
  - pathogens in, anaerobic, 108-110
    - in immunocompromised patients, 32-33
    - in pediatric patients, 17-20
  - pediatric, 17-30
  - PEDS bottle system for, 24
  - peripheral, in catheter-related infections, 55
  - processing of, 63-66
  - quantitative, in catheter-related infections, 55-56
  - rapid detection and identification methods for, 181-195
    - biochemical, 184-187
    - chromatography in, 191
    - clinical relevance of, 182-184
    - immunologic, 187-191
    - in immunocompromised patients, 41
    - nucleic acids in, 191
  - reporting of, in immunocompromised patients, 42
  - safety in, 127-128
  - semiquantitative, in catheter-related infections, 54-55
  - Septi-Chek system for. See *Septi-Chek system*.
  - signal broth displacement system for, 139-140
  - specimen collection for, 59-68
    - anaerobic, 110
    - in immunocompromised patients, 33-35
    - in pediatric patients, 20-23
    - needle switching in, 62-63
    - skin antisepsis in, 60-61
    - timing of, 60
    - universal precautions in, 61

## venipuncture vs. catheter specimens

- in, 61-62
- specimen transport in, 63
- subcultures in, 76-78
- terminology of, 1-3
- timing of, 70-71
- true-positive, 2-3, 42-43
- variables in, 3-6
- vented bottles in, 135-136
- viral, in immunocompromised patients, 39-40
- volume of, 3, 71
  - in fungemia, 89
  - in pediatric patients, 22-23
- Blood donors, HIV detection in, polymerase chain reaction in, 322
- Blood gases, measurement of, biosensors in, 466-468
  - sample collection for, 545
- Blood-to-broth ratio, in blood cultures, 72-73
- Body fluids, lead measurement in, 657-658
- Bone, lead measurement in, 657
  - methods for, 662-664
- Bone marrow, culture of, in immunocompromised patients, 42
  - in pediatric patients, 21
  - lead measurement in, 657
- Brain, disseminated intravascular coagulation in, 734
- lead measurement in, 657
- Brain-heart infusion broth, in fungal blood cultures, 85-86, 88, 91
- Branch DNA signal amplification, in HIV detection, 337
- Brucella*, blood culture of, 120-123
- Burns, disseminated intravascular coagulation in, 733-734
- N-Butyl deoxynojiramicin, in HIV infection, 376-377
- Caffeic acid phenylethyl ester, in HIV infection, 372
- Calanolide, HIV resistance to, 399
- Calibration, in alternate-site testing, 593
- Campothecin, in HIV infection, 372
- Campylobacter*, blood culture of, 123-124
- Canadian Society of Clinical Chemists, position on alternate-site testing, 456-457
- Candida*, blood culture of, 92
  - rapid detection of, in blood, 189-190
- Cand-Tec test, for rapid microorganism identification, 189-190
- Capillary blood, for blood culture, 21
- Carbon dioxide, monitoring of, biosensors in, 466-468
- Cardiobacterium hominis*, blood culture of, 124

- Cardiovascular prostheses, disseminated intravascular coagulation from, 734-735
- Cardiovascular system, lead poisoning effects on, 652
- Cartridge, of multichannel analyzer, 464-465
- Castanospermine, in HIV infection, 376
- Catheters, blood culture sampling from, in catheter-related infections, 55-56  
in immunocompromised patients, 33-34  
in pediatric patients, 20-21  
vs. venipuncture, 61-62  
infections related to, blood cultures in, 51-58
- Cavernous hemangioma, giant, disseminated intravascular coagulation in, 734
- Central nervous system, lead poisoning effects on, 650-651
- Cerebrospinal fluid, HIV in, 340
- Certification, of analysts for alternate-site testing, 585-586
- Chelation provocation test, in lead poisoning, 659-660, 663-664
- Chelation therapy, in lead poisoning, 655
- Chemotherapy, blood-borne infection in, 32
- Chloride determination, in portable analyzer, 486
- Chondroitin sulfate, in coagulation regulation, 701-702  
therapy with, monitoring of, 833
- Chromatography, in rapid microorganism detection, in blood, 191
- Chromium, radioactive, in T-lymphocyte cytotoxicity assay, 277
- Chromogenic assay instrumentation, for coagulation evaluation, 715-720
- Chronolog instruments, for platelet function evaluation, 721
- Ciba Corning instruments, for coagulation evaluation, 486, 714-715
- Circulating anticoagulants, 795-812  
coagulation factor inhibitors, 803-808  
factor IX inhibitors, 807  
factor VIII inhibitors, 803-807  
fibrinogen degradation products. See under *Fibrinogen*.  
fibrinogen inhibitors, 807  
heparinlike paraproteins, 802  
in acquired von Willebrand's disease, 808  
lupus, 795-801  
paraprotein inhibitors, 801  
pharmacologic agents, 802-803
- Cirrhosis, of liver, coagulopathies in, 771-773
- CLIA. See *Clinical Laboratory Improvement Amendments*.
- Clinical Laboratory Improvement Amendments, impact of, 494-495, 506  
on quality management, 550-552  
regulations of, alternate-site testing and, 607  
for personnel, 584-585  
vs. Veterans Affairs procedure, 507-508  
test complexity categories of, 583-584
- Clostridia, blood culture of, 109
- Clot formation, automated instrumentation based on, 711-715
- Clot Signature Analyzer, for coagulation evaluation, 715
- COAG-1 device, 486
- Coag-a-Mate instruments, for coagulation evaluation, 712
- Coagglutination tests, for rapid microbial identification, 187-188
- Coagulase test, for microorganism identification, in blood cultures, 185
- Coagulation assay, phospholipid-dependent, for lupus anticoagulants, 798
- Coagulation factors, 691-692. See also under *Factor*.  
assays for, in disseminated intravascular coagulation, 743  
deficiency of, in cirrhosis, 771-772  
inhibitors of, laboratory assessment of, 807-808  
replacement of, in disseminated intravascular coagulation, 755-756
- Coagulation system, disorders of, circulating anticoagulants in, 795-812  
in disseminated intravascular coagulation. See *Disseminated intravascular coagulation*.  
in liver disease. See *Liver disease*, *coagulopathies of*.  
evaluation of, automated instrumentation for, 709-728  
chromogenic assay, 715-720  
clot-based, 711-715  
immunologic assay, 722-725  
platelet, 720-722  
quality control of, 710-711, 725-726  
bedside, 486  
in disseminated intravascular coagulation, global tests in, 742-745  
molecular markers in, 745-750  
inhibitors of, 698-699  
pathways of, 689-692  
proteins of, coagulation factors, 689-691  
fibrin, 691-692  
thrombin, 691  
regulation of, 698-699  
defects of, in cirrhosis, 772-773
- Coagulometers, in oral anticoagulation monitoring, 819-820



- Cobasbact antibiotic susceptibility testing system, 177
- Coccidioides immitis*, blood culture of, 93
- Colic, lead, 652
- Collagen-induced aggregation test, in antiplatelet agent therapy monitoring, 838-839
- Collagen-vascular disease, disseminated intravascular coagulation in, 734
- College of American Pathologists, accreditation for alternate-site testing, checklist for, 475-480, 484, 608-616 position on alternate-site testing, 457 Q-Probes Study, 475-480, 482, 484 quality control testing requirements of, 482
- Communication, in alternate-site testing, 559-567
- Competency testing requirements, in alternate-site testing, 597
- Complement system, activation of, 695-696
- Complete blood count, in lead poisoning, 660-661
- Computer system, for communication in alternate-site testing, 559-567
- Constipation, in lead poisoning, 652
- Consumptive coagulopathy. See *Disseminated intravascular coagulation*.
- Contaminants, in blood cultures, 11 fungal, 91-92
- Continuous-monitoring blood culture systems, 157-166  
BacT/Alert, 161-163  
BACTEC, 157-161, 163-164  
bioMerieux Vital, 165  
Difco ESP, 164-165  
MicroScan, 165-166
- Corticosteroids, in disseminated intravascular coagulation, thrombogenic effects of, 741-742
- Coulter instruments, for coagulation evaluation, 717-718  
for platelet function evaluation, 721
- Coumarin, side effects of, 837
- Coumatrak instruments, for coagulation evaluation, 486, 714-715
- Counterimmunoelectrophoresis, for rapid microbial identification, 187
- Credentialing, of analysts for alternate-site testing, 585-586
- Critical values, in alternate-site testing, 594
- Cross-training, of personnel, in patient-centered unit, 526, 528-529, 535-536
- Cryptococcemia, antigen detection in, 190  
blood culture in, 92
- CTS instrument, for coagulation evaluation, 717
- Culture media, for blood cultures, 71-72  
biphasic, 135-137  
hypertonic, 24, 76  
in anaerobic bacteremia, 110  
in BACTEC systems, 151, 153, 155  
in BioArgos system, 156  
in brucellosis, 122  
in *Campylobacter* bacteremia, 123  
in fungemia, 85-86, 88, 90-91  
in mycobacteremia, 101-102  
in mycoplasmaemia, 126  
in pediatric patients, 23-25  
in vitamin B<sub>12</sub>-dependent streptococcal infections, 127  
manual systems, 133-135  
for *Legionella*, 124-125
- Cyclic adenosine monophosphate, in platelet interaction, 685-686
- Cytokines, from cytotoxic T lymphocytes, in HIV infection pathogenesis, 287
- Cytomegalovirus infection, blood culture in, 39-40  
disseminated intravascular coagulation in, 733
- Cytotoxic T lymphocytes. See under *T lymphocytes*.
- Data base, for laboratory testing information, 563
- Dataclot instruments, for coagulation evaluation, 714
- ddC. See *Zalcitabine (ddC)*.
- ddl. See *Didanosine (dideoxyinosine, ddl)*.
- D-dimer assay, in disseminated intravascular coagulation, 744
- Decentralized testing. See *Alternate-site testing*.
- Defibrination syndrome. See *Disseminated intravascular coagulation*.
- Defibrotide, in disseminated intravascular coagulation, 755
- Delavirdine, HIV resistance to, 397, 399
- Dementia, AIDS, cytotoxic T lymphocytes in, 286-287
- Densitometry, in von Willebrand factor multimer assessment, 786
- Deoxynojiramicin, in HIV infection, 376
- Dermatan sulfate, in coagulation regulation, 701-702  
therapy with, monitoring of, 833
- Desmopressin, in von Willebrand's disease, 791
- Detector device, in biosensor, 460-461
- Diagnostica Stago instruments, for coagulation evaluation, 719-720
- DIC. See *Disseminated intravascular coagulation*.
- Didanosine (dideoxyinosine, ddl), HIV resistance to, 396, 398  
as pathogenic factor, 408-409  
biochemical bases of, 406-407



- in combination therapy, 400
- laboratory monitoring of, 411
- in HIV infection, monitoring of, polymerase chain reaction in, 327
- virus burden response to, 305-306
- Dideoxyguanosine, HIV resistance to, biochemical bases of, 406
- Difco ESP system, for blood cultures, 164-165
- Dilute partial thromboplastin time, in lupus anticoagulants, 798
- Dipyridamole, in disseminated intravascular coagulation, 758
- Directigen test, for rapid microbial identification, 188
- Disk diffusion method, for antibiotic susceptibility testing, 173, 175
- Disseminated intravascular coagulation, 729-768
  - compensated, 739
  - treatment of, 757-758
  - controversy on, 729
  - definition of, 730
  - diagnosis of, clinical, 739-740
    - laboratory, 742-750, 802
    - global coagulation tests in, 742-745
    - molecular markers in, 745-750
    - severity scoring system for, 750-752
  - etiology of, 731-735
    - vs. treatment options, 752-753
  - fulminant, treatment of, 752-757
  - historical perspectives of, 731
  - in liver disease, 772-773
  - in obstetrical accidents, 731-732
  - in pregnancy, 731-732
  - low-grade, treatment of, 757-758
  - monitoring in, 759
  - morphologic findings in, 740-742
  - pathophysiology of, 735, 737-739
  - scoring system for, in diagnosis, 750-752
  - in treatment, 758-759
  - severity of, assessment of, 750-752
  - spectrum of, 730
  - terminology of, 730
  - treatment of, 752-759
- DNA probes, in rapid microorganism detection, 191
- Drugs, abuse of, urine screening in, portable device for, 487
- antiretroviral. See *Antiretroviral drugs*.
- antithrombotic. See *Anticoagulants (pharmacologic)*.
- lead interaction with, 438
- Dynatech instruments, for coagulation evaluation, 725
- EBP-1, in HIV gene transcription, 244
- Eclampsia, disseminated intravascular coagulation in, 731-732
- Economic aspects, of alternate-site testing, 453, 570-571
  - consolidation in multihospital systems, 506
  - in glucose determination, 485-486
  - quality control and, 541-542
- Education. See also *Training*.
  - for alternate-site testing, 577-578, 597-601
    - continuing, 599-602
  - Eikenella corrodens*, blood culture of, 124
  - Elderly persons, blood cultures in, pediatric systems for, 65
  - immunosuppression in, blood-borne infection in, 33
  - lead poisoning in, 438-439
- Electra instruments, for coagulation evaluation, 712, 719
- Electrochemical biosensors, 464-465
- Electrophoresis, in Western blot test, for HIV, 261
- ELISA. See *Enzyme-linked immunosorbent assay*.
- Embolism, amniotic fluid, disseminated intravascular coagulation in, 731
- Embolization, of esophageal varices, coagulopathies in, 776-777
- Emergency care, testing in, 627
  - biosensors in, 462-463, 465
  - perceived performance of, 641
  - personnel for, 631
  - proficiency, 637
  - revenues from, 634
- Encephalopathy, lead, 650-651
- Endothelium, vascular, in hemostasis, 678-680
  - injury of, disseminated intravascular coagulation in, 735
- Endotoxin, disseminated intravascular coagulation from, 733
- env* gene and gene product, 204-206, 243
- cytotoxic T lymphocytes recognizing, 283-284
- Environmental samples, for lead measurement, 660
- Enzyme-linked immunosorbent assay, for coagulation evaluation, 723-725
  - for fibrinopeptides, in disseminated intravascular coagulation, 747
  - for HIV antibodies, 258-260
  - for plasmin complexes, in disseminated intravascular coagulation, 748
- Epsilon-aminocaproic acid, in disseminated intravascular coagulation, 757
- Erythrocyte(s), lead poisoning effects on, 649-650
- Erythrocyte protoporphyrin, measurement of, in lead poisoning, 661-662
- Esophageal varices, embolization of, coagulopathies in, 776-777

- ESP system, for blood cultures, in fungemia, 88-89
- Ethanol gelation test, for fibrinogen degradation products, 802
- in disseminated intravascular coagulation, 743-744
- Euglobin lysis time, in cirrhosis, 772
- Expiration dates, of reagents, 593-594
- FACSCAN instrument, for platelet function evaluation, 721
- FACSTAR instrument, for platelet function evaluation, 721
- Factor II, deficiency of, in cirrhosis, 771
- inhibitors of, laboratory assessment of, 807-808
- Factor V, deficiency of, in cirrhosis, 772
- inhibitors of, laboratory assessment of, 807-808
- Factor VII, deficiency of, in cirrhosis, 771
- inhibitors of, laboratory assessment of, 807-808
- Factor VIII, antigen of, assay for, in von Willebrand's disease, 782
- assay for, in von Willebrand's disease, 782
- infusion with, disappearance assay for, in factor VIII inhibitor disorders, 805
- inhibitors of, laboratory assessment of, 803-807
- replacement of, in von Willebrand's disease, 791
- von Willebrand factor binding to, 789
- Factor IX, deficiency of, in cirrhosis, 771
- inhibitors of, laboratory assessment of, 807
- Factor IXa, formation of, 689-690
- Factor X, deficiency of, in cirrhosis, 771
- Factor Xa, formation of, 690-691
- Factor XI inhibitors, laboratory assessment of, 808
- Factor XIII inhibitors, laboratory assessment of, 807-808
- Fastidious microorganisms, blood culture for, 119-131
- Brucella*, 120-123
- Campylobacter*, 123-124
- HACEK bacteria, 124
- Legionella*, 124-125
- Mycoplasma*, 125-126
- safety issues in, 127-128
- vitamin B<sub>6</sub>-dependent streptococci, 127
- Ferrochelatase, inhibition of, in lead poisoning, 650
- Fetus, lead measurement in, 658
- lead poisoning in, 653
- retained, disseminated intravascular coagulation in, 731
- Fever, in disseminated intravascular coagulation, 739
- Fiberoptics, in intravascular monitoring, 709
- Fibrin(ogen), abnormal, in liver disease, 770-772
- deficiency of, in cirrhosis, 772
- degradation products of, 695, 699
- in disseminated intravascular coagulation, 737-738, 743-745
- laboratory assessment of, 801-802
- deposition of, in disseminated intravascular coagulation, 735, 737, 740
- formation of, 691-692
- inhibitors of, laboratory assessment of, 807
- Fibrinolysis, heparin in, 833
- Fibrinolytic system, 692-695
- activation of, in liver transplantation, 775
- in peritoneovenous shunt installation, 776
- assays for, in disseminated intravascular coagulation, 747-748
- defects of, in cirrhosis, 772-773
- inhibitors of, 694
- in disseminated intravascular coagulation treatment, 756-757
- Fibrinopeptides, elevated, in liver disease, 773
- measurement of, in disseminated intravascular coagulation, 746-747
- Fibrometer instrument, for coagulation evaluation, 712-714
- Fibronectin, 700-701
- Floor testing, 627
- perceived performance of, 643
- personnel for, 633
- proficiency, 640
- revenues from, 636
- Flow cytometry, in platelet function evaluation, 720-722
- Flow Laboratories instruments, for coagulation evaluation, 725
- Fluorescent stains, for blood culture, 40
- Food, lead concentrations in, 427
- Foscarnet, HIV resistance to, 396
- Free erythrocyte protoporphyrin, vs. zinc protoporphyrin, 654
- Fungemia, 83-97
- blood cultures in, catheter-related, 51-58
- evolution of, 85-89
- in immunocompromised patients, 36-38
- variables in, 89-92
- epidemiology of, 11-13
- mortality in, 13-15
- rapid organism identification in, 189-191
- significance of, 83-84
- sources of, 13

- Gabexate, in disseminated intravascular coagulation, 755
- gag* gene and gene product, 204-206, 211
- cytotoxic T lymphocytes recognizing, 278-279
- Gas-liquid chromatography, in rapid microorganism detection, 191
- Gastrointestinal system, lead poisoning effects on, 652
- Gelation tests, in disseminated intravascular coagulation, 743-744
- GEM 91, in HIV infection, 374
- GEM Premier blood gas tester, 487
- Gene therapy, for HIV infection, 380-382
- Genetic factors, in von Willebrand's disease, 789-790
- Genotypic assays, for HIV drug resistance, 410-411
- Giant cavernous hemangioma, disseminated intravascular coagulation in, 734
- Glucose determination, bedside, 474-480
- accuracy of, 477-479
- cost of, 485-486
- devices for, 474-476
- error consequences in, 479-480
- precision of, 476-477
- program components for, 481-485
- quality assurance in, 481-485
- regulation of, 480
- biosensors in, 464-465, 469
- in alternate sites, guidelines for, 513-516
- protocol for, 521-522
- preanalytical errors in, 545
- Glucose oxidase, in glucose monitoring devices, 475
- Glycoproteins, platelet, 687-688
- inhibitors of, therapeutic monitoring of, 839
- Glycosaminoglycan therapy, monitoring of, 831
- synthetic compounds, 831
- Glycosylation, in HIV replication, inhibitors of, 376-377
- Gout, with lead poisoning, 424
- Gram-negative bacilli, anaerobic, blood culture of, 108-109
- Gram-positive bacilli, anaerobic, blood culture of, 109
- Gram-positive cocci, anaerobic, blood culture of, 110
- Granulocytopenia, blood-borne infection in, 32
- HACEK bacteremia, blood culture in, 124
- Haemophilus*, blood culture of, 124
- Hair, lead measurement in, 657
- Helena Laboratories instruments, for platelet function evaluation, 721
- Hemangioma, giant, disseminated intravascular coagulation in, 734
- Hematocrit determination, in portable analyzer, 486
- Hematologic disorders, disseminated intravascular coagulation in, 733
- Hematopoietic system, lead poisoning effects on, 649-650
- Hemochron instrument, for coagulation evaluation, 714
- Hemocue device, 487
- Hemoglobin determination, portable device for, 487
- Hemolysis, intravascular, disseminated intravascular coagulation in, 732
- Hemolytic-uremic syndrome, vs. disseminated intravascular coagulation, 734
- Hemophilia, factor VIII inhibitors in, 803
- Hemostasis. *See also Coagulation system.*
- definition of, 677
- in disseminated intravascular coagulation. *See Disseminated intravascular coagulation.*
- in liver disease. *See Liver disease, coagulopathies of.*
- in von Willebrand's disease, 781-794
- physiology of, 677-707
- compartments involved in, 677
- fibronectin in, 700-701
- plasma protein function in, 688-699
- coagulation system, 689-692
- complement activation, 695-696
- fibrin, 691-692
- fibrinolytic system, 692-695
- inhibitor systems, 698-699
- kinin generation, 697-698
- thrombin, 691
- platelet function in, 681-688
- proteoglycans in, 701-702
- vascular function in, 678-680
- Heparan sulfate, in coagulation regulation, 701-702
- therapy with, monitoring of, 833
- Heparin, activity of, 826
- anticoagulant vs. antithrombotic, 832
- antithrombin III affinity of, 826
- in coagulation regulation, 701-702
- in fibrinolysis, 833
- low-dose, 826
- measurement of, 802-803
- in plasma, 827
- side effects of, monitoring for, 833-835
- therapy with, in disseminated intravascular coagulation, 752, 754-755, 758
- monitoring of, 826-835
- high molecular weight, 826-827, 829
- low molecular weight, 826-830
- unfractionated, 826

Heparin (*Continued*)

- very low molecular weight, 832
- thrombocytopenia from, 834-835
- Heparinlike molecules, laboratory
  - assessment of, 802
  - therapy with, monitoring of, 832
- Hepatic artery, thrombosis of, in liver transplantation, 776
- Hepatitis, coagulopathy in, 770-771
  - disseminated intravascular coagulation in, 733
- Hepcon instruments, for coagulation evaluation, 714
- HEPT compounds, HIV resistance to, 397, 399
- Heptest, in heparin therapy monitoring, 827-828
- Hereditary hemorrhagic telangiectasia, disseminated intravascular coagulation in, 734
- Hewlett-Packard instruments, for coagulation evaluation, 725
- Hexagonal phospholipid neutralization test, in lupus anticoagulants, 798-799
- High molecular weight fibrinogen complexes, in liver disease, 773
- High-pressure liquid chromatography, in rapid microorganism detection, 191
- Hirudin, in disseminated intravascular coagulation, 755
  - therapy with, monitoring of, 835-836
- Histoplasma capsulatum*, blood culture of, 155
- HIV. See *Human immunodeficiency virus*.
- HIV infection. See *Human immunodeficiency virus* infection.
- HIVEN 86A, in HIV gene transcription, 244
- Human immunodeficiency virus (type 1),
  - ancillary proteins of, 212-216
  - antibodies to, serologic assays for, 257-269
  - assays for, 307-308
    - in burden determination, 305
    - clinical management and, 307-308
    - clinical trial design and, 306-307
    - in latent period, 240-242
    - polymerase chain reaction in, 325-328
    - in situ polymerase chain reaction in, 240-241, 351-365
    - polymerase chain reaction in, 313-333
    - reverse transcriptase-polymerase chain reaction in, 335-349
    - serologic, 257-269
    - burden of, 301-311
      - drug resistance and, 394-395
      - measurement of, 305
      - clinical management and, 307-308
      - clinical trial design and, 306-307
      - in latent period, 240-242
      - polymerase chain reaction in, 325-328
      - phenotype significance in, 304-305
      - vs. antiretroviral therapy response, 305-306
      - vs. disease progression, 302-305
      - cells infected by, 205, 207
      - drug resistant. See *Antiretroviral drugs*, *HIV resistance* to.
      - escape of, from cytotoxic T lymphocyte recognition, 287-290
      - genes of, 205
        - expression of, latency and, 242-246
        - regulation of, 208-211
        - virus burden and, 303
      - genomic organization of, 204-205
      - latency and, 242-246
      - in body fluids, 340-341
      - life cycle of, 203-204
      - long terminal repeat of, 204, 208-210, 243-244
      - molecular biology of, 203-220
      - phenotype of, vs. disease progression, 304-305
      - progression of, vs. virus burden, 302-305
      - provirus of, 240-241, 246-248
      - replication of, 211-212
        - modes of, 302
        - stages of, drugs affecting, 368-380
      - reverse transcription of, 207-208
      - strains of, vs. T-lymphocyte depletion kinetics, 232-234
      - tissue dissemination of, polymerase chain reaction studies of, 324
      - variation of, escape from T-lymphocyte recognition and, 288-289
      - vs. type 2, polymerase chain reaction differentiation of, 324
  - Human immunodeficiency virus (type 2),
    - genes of, 205-206
    - polymerase chain reaction identification of, 324
      - Western blot test for, 261-262
  - Human immunodeficiency virus infection, asymptomatic. See also subhead: *latency* in.
    - polymerase chain reaction in, 321-326
      - serologic assays in, 263-264
    - blood culture in, for HIV, 39
    - blood-borne infection in, 33, 36
    - diagnosis of, polymerase chain reaction in, 316-319
    - disseminated intravascular coagulation in, 733
    - early events in, 205, 207-208

- in pediatric patients, cytotoxic T lymphocyte function in, 285-286
- polymerase chain reaction detection of, 323
- latency in, 239-255. See also subhead: *asymptomatic*.
  - evidence for, 240-242
  - genome structure contribution to, 242-246
  - host factors in, 246-248
- lupus anticoagulants in, 798
- mathematical model of, 234
- mycobacteremia in, 99-103
- natural history of, neutralizing antibodies in, 264-266
- pathogenesis of, cytotoxic T lymphocytes in, 286-287
  - drug resistance and, 408-410
- polymerase chain reaction studies of, 324-327
- seroconversion in, polymerase chain reaction detection before, 321-323
- T lymphocytes in. See under *T lymphocytes*.
- treatment of. See also *Antiretroviral drugs*.
  - gene therapy in, 380-382
  - polymerase chain reaction monitoring of, 327-328
  - virus burden response to, 305-306
  - vs. virus burden, 305-308
- vaccines for, cytotoxic T lymphocytes induced by, 290-292
- viremia in, vs. disease progression, 303-304
- virus burden in. See *Human immunodeficiency virus (type 1)*, burden of.
- Human leukocyte antigens, on cytotoxic T lymphocytes, HIV-specific, 274-275
- Hyaline microthrombi, in disseminated intravascular coagulation, 741
- Hyaluronic acid, in coagulation regulation, 701-702
- Hypercoagulability, lupus anticoagulants in, 797
- Hypericin, in HIV infection, 372
- Hypersensitivity, to heparin, 835
- Hypertension, in lead poisoning, 652
- Hypertonic media, for blood cultures, 24, 76
- Hypotension, in disseminated intravascular coagulation, 739
- Hypoxia, in disseminated intravascular coagulation, 739
- Immunization, intracellular, in HIV infection, 380-382
- Immunoadhesins, CD4, antiretroviral activity of, 371
- Immunocapture reverse transcriptase test, for HIV, 263
- Immunocompromised patients. See also *Human immunodeficiency virus infection*.
  - blood cultures in, 31-49
    - antibiotic effect in, elimination of, 40
    - fluorescent stains for, 40
    - fungal, 37-38
    - historical aspects of, 31-32
    - incubation of, duration of, 41
    - interpretation of, 42-43
    - mycobacterial, 38-39
    - negative, 41-42
    - pathogens in, 32-33
    - rapid detection and identification
      - methods for, 41
    - rationale for, 31-32
    - reporting of, 42
    - specimen collection for, 33-35
    - systems for, 35-40
    - viral, 39-40
  - Immunofluorescence assay, for HIV antibodies, 258-259
  - Immunologic methods, for coagulation evaluation, 722-725
    - for rapid microbial identification, 187-191
  - Immunomodulation, HIV in, 225-228
  - In situ polymerase chain reaction, in HIV detection, 351-365
    - in latent period, 240-241
    - in replication studies, 356
    - percentage of cell infected, 356-357, 359-362
    - sensitivity of, 357-358
    - techniques for, 352-355
  - In vivo testing, 456, 573-574
    - biosensors in, 468-469
    - definition of, 456
  - Incubation, of blood cultures. See under *Blood cultures*.
  - Infection, disseminated intravascular coagulation in, 732-733
  - Instrument maintenance, in alternate-site testing, 595-596
  - Integrase inhibitors, in HIV infection, 372
  - Intensive care unit, testing in, 627
    - biosensors in, 463-464
    - perceived performance of, 641
    - personnel for, 631
    - proficiency, 638
    - revenues from, 634
    - vs. monitoring, 588
  - Interferons, in HIV infection, 376, 379-380
    - from cytotoxic T lymphocytes, 287
  - International normalized ratio, in oral anticoagulation monitoring, 814-815, 817-821
  - International sensitivity index, in oral anticoagulation monitoring, 814-820

- International Technidyne instruments, for platelet function evaluation, 721
- Intracellular immunization, in HIV infection, 380-382
- Intravascular monitoring, biosensors for, 468
- Ion-selective electrode, in alternate-site testing, 464-465, 486
- Iron metabolism, lead poisoning and, 437
- Isolator system, for blood cultures, 142-144  
in anaerobic bacteremia, 112-113  
in pediatric patients, 24
- i-STAT analyzer, 464-465, 486
- Joint Commission on Accreditation of Healthcare Organizations, accreditation guidelines, in alternate-site testing, 607, 616-622  
manual for all-site testing, 480  
requirements of, 520, 585-586  
quality control testing, 482
- Kallikrein, formation of, 697-698
- Kaolin clotting time test, in lupus anticoagulants, 798-799
- Kaposi's sarcoma, interferon alpha for, 379-380
- Kasabach-Merritt syndrome, disseminated intravascular coagulation in, 734
- Kidney, lead poisoning effects on, 652
- Kingella kingae*, blood culture of, 124
- Kinins, generation of, in disseminated intravascular coagulation, 738  
in hemostasis, 697-698
- Koagulab instruments, for coagulation evaluation, 712
- L697,661 (antiretroviral drug), HIV resistance to, 394, 397, 399  
as pathogenic factor, 408
- Lactation, lead poisoning in, 439
- Langerhans cells, HIV in, 341
- Latency, in HIV infection, 239-255, 263-264, 321-326
- Latex agglutination assay, for coagulation evaluation, 724  
for rapid microbial identification, 187-188
- Laurell method, for coagulation evaluation, 723-724
- LCS system, for fungal cultures, 85-86, 88, 90
- "Lead lines," in lead poisoning, 663
- Lead poisoning, 423-444, 649-668  
aging and, 438-439  
alcohol ingestion and, 438  
blood lead levels in, interpretation of, 655-656  
body burden of, vs. toxicity, 653-656  
cardiovascular effects of, 652  
central nervous system effects of, 650-651  
control of, 430-431, 433-434  
definition of, blood levels in, 424-425  
drug interactions in, 438  
environmental contamination and, 425-427  
from environmental exposure, 431-434  
from increased tissue lead mobilization, 439  
from occupational exposure, 428, 430-431  
from paint, 424-425, 427  
from recreational activities, 434  
from substance abuse, 434-435  
gastrointestinal effects of, 652  
hematopoietic effects of, 649-650  
historical background of, 423-424  
in developing nations, 427-428  
in fetus, 653  
in pediatric patients, 427, 431-434  
blood lead level interpretation in, 655-656  
body burden of, 655  
central nervous system effects in, 651  
newborn, 653  
in pregnancy, 653  
iron interactions in, 437  
lead absorption in, 435-436  
pandemics of, 423-424  
renal effects of, 652  
reproductive effects of, 653  
sources of, 428  
testing in, methods for, 660-664  
protoporphyrins in, 654-655  
quality control in, 664  
sample collection for, 658-660  
specimens for, 656-658  
toxicokinetics of, 436-437  
trace mineral interactions in, 438  
treatment of, in children, 655  
vitamin D metabolism and, 438
- Leader binding protein-1, in HIV gene transcription, 245
- Legionella*, blood culture of, 124-125
- Lentiviruses, genomic organization of, 204-205
- LeVeen shunt, in disseminated intravascular coagulation treatment, 735
- Ligase chain reaction, in HIV detection, 262-263, 337
- Limited service laboratory testing, definition of, 455

- Linearity checks, in alternate-site testing, 594
- Liver, peritoneovenous shunt surgery involving, coagulopathies in, 776  
resection of, coagulopathies in, 776  
transplantation of, coagulopathies in, 774-776
- Liver disease, coagulopathies of, 769-780  
in cirrhosis, 771-773  
in mild disorders, 770-771  
in moderate disorders, 770-771  
in severe disorders, 770-771  
in surgical situations, 774-777  
vitamin K deficiency and, 773-774  
disseminated intravascular coagulation in, 733
- LKB instruments, for coagulation evaluation, 725
- Local area network, for laboratory information communication, 565-566
- Long terminal repeat, of HIV, 204, 208-210, 243-244
- Lumi-Aggregometer, for platelet function evaluation, 721
- Lung, hyaline microthrombi in, in disseminated intravascular coagulation, 741
- Lupus anticoagulants, laboratory assessment of, 795-801
- Lymphocytes, T. See *T lymphocytes*.
- Lymphoid tissue, HIV in, 341
- Lysis-centrifugation system, for blood cultures, 142-144  
in anaerobic bacteremia, 112-113  
in brucellosis, 122  
in pediatric patients, 24
- Lysostaphin test, for microorganism identification, in blood cultures, 184-185
- Macrophages, alveolar, in HIV-specific cytotoxic T lymphocyte detection, 272-273
- Maintenance, instrument, in alternate-site testing, 595-596
- Major histocompatibility complex, HIV infection effects on, 226-228
- Malassezia*, blood culture of, 24-25, 92-93
- Malignancy, blood-borne infection in, 32  
disseminated intravascular coagulation in, 733
- Manchester comparative reagent, in oral anticoagulation monitoring, 814
- Manual, policy and procedure, for alternate-site testing, 578-582, 598  
maintenance instructions in, 596  
safety policy in, 596-597
- MDA instrument, for coagulation evaluation, 719
- Media. See *Culture media*.
- Medical Laboratory Automation instruments, for coagulation evaluation, 712, 719
- Membrane glycoproteins, platelet, 687-688
- Meritec test, for rapid microbial identification, 188
- 12-Methoxydodecanoic acid, in HIV infection, 377
- Micro-ID system, for rapid microbial identification, 186-187
- MicroScan system, for antibiotic susceptibility testing, 176  
for blood cultures, 165-166
- Microscopy, in bacteremia, 26  
in blood culture. See *Blood cultures, direct microscopy of*.
- physician-performed, 583-584
- Minerals, dietary, lead interaction with, 438
- "Miniheparin" therapy, monitoring of, 832
- Mobile laboratory, 572
- Molecular markers, in disseminated intravascular coagulation diagnosis, 745-750
- Molecular recognition element, in biosensor, 460-461
- Mononuclear blood cells, peripheral. See *Peripheral blood mononuclear cells*.
- Multihospital systems, alternate-site testing in. See *Alternate-site testing, consolidation in multihospital systems*.
- Multiplex method, for polymerase chain reaction, in HIV infection, 319
- Murine leukemia virus, genes of, 204, 206
- Mycobacteremia, 99-105  
blood cultures in, 38-39, 101-102  
bone marrow cultures in, 102-103  
epidemiology of, 99-100  
in immunocompromised patients, 36, 38-39  
liver biopsy cultures in, 103  
microscopic detection of, 100-101
- Mycoplasma*, blood culture of, 125-126
- Myocardial infarction, disseminated intravascular coagulation in, 734
- Myristoylation, in HIV replication, inhibitors of, 377-378
- Near-infrared spectroscopy, in blood gas analysis, 467-468
- Needles, switching of, in blood culture sampling, 62-63
- nef* gene and gene product, 205-206, 211-214  
cytotoxic T lymphocytes recognizing, 284-285
- Negative regulatory element, of HIV gene, 244-245



- Neomycin B, in HIV infection, 376
- Neonates, lead poisoning in, 653
- Nephropathy, lead, 652
- Networks, for laboratory information communication, 563, 565-566
- Neuropathy, in lead poisoning, 650-651
- Neutralizing antibodies, in HIV infection, 264-266
- Neutropenia, blood-borne infection in, 32
- Nevirapine, HIV resistance to, 397, 399  
as pathogenic factor, 408, 410  
biochemical bases of, 404, 407  
in combination therapy, 400
- New Oxford method, for factor VIII inhibitor assessment, 805-806
- NO donors, therapy with, monitoring of, 840
- Nocardia*, blood culture of, 93
- Nuclear factors, in HIV gene expression, 210, 244
- Nucleic acid probes, in rapid microorganism detection, 191
- Obstetrical accidents, disseminated intravascular coagulation in, 731-732  
treatment of, 753-754
- Occupational exposure, to lead, 428, 430-431
- Occupational Safety and Health Administration, lead exposure regulations of, 430-431
- Office testing, physician, definition of, 455-456
- Oligonucleotide(s), antisense, in HIV infection, 373-374
- Oligonucleotide solution hybridization technique, in HIV detection, 317
- Oncornaviruses, genomic organization of, 204-205
- Oral anticoagulation, monitoring of, 813-823  
historical background of, 813-815  
international normalized ratios in, 817-821  
reference preparations for, 815-817  
thromboplastin calibration in, 817, 820
- Organon Teknika instruments, for coagulation evaluation, 712, 725  
for platelet function evaluation, 721, 729
- Ortho Diagnostic Systems instruments, for coagulation evaluation, 712, 717  
for platelet function evaluation, 721
- Osteoporosis, in heparin therapy, 835
- Oxygen, monitoring of, biosensors in, 466-468
- p24 antigen, assays for, 262-264, 307-308
- in drug resistance, 412
- Paint, lead-containing, exposure to, 424-425, 427
- Panic (critical) values, in alternate-site testing, 594
- Paracoagulation tests, 737  
for fibrinogen degradation products, 802
- Paraproteins, heparinlike, laboratory assessment of, 802  
inhibitors of, laboratory assessment of, 801-802
- Partial thromboplastin time, dilute, in lupus anticoagulants, 798  
in von Willebrand's disease, 789
- Patient-centered units, 525-538  
definition of, 526  
laboratory for, 527, 573  
cross-training in, 526, 528-529, 535-536  
instrumentation for, 528  
personnel performance in, 535-536  
pilot project for, 527-535
- Pediatric patients, blood cultures in, 17-30  
anaerobic, 25  
cost considerations in, 27  
direct microscopy of, 26  
incubation of, 25-26  
laboratory issues in, 23-26  
media for, 23-25  
number of, 21-22  
pathogens in, 17-20  
specimen collection for, 20-23  
timing of, 22  
volume of, 22-23
- HIV infection in, cytotoxic T lymphocyte function in, 285-286  
polymerase chain reaction detection of, 323
- HIV testing in, 262  
lead exposure in, 427, 431-434  
lead poisoning in, 651, 653  
blood lead level interpretation in, 655-656  
treatment of, 655
- PEDS bottle system, for blood cultures, 24
- Pentasaccharide therapy, monitoring of, 832
- Pentosan polysulfate therapy, monitoring of, 832
- Peptococcus*, blood culture of, 110
- Peripheral blood, culture of, in catheter-related infections, 55
- Peripheral blood mononuclear cells, cytotoxic T lymphocytes in, HIV-specific, 272-274, 278-279, 283
- HIV burden in. See *Human immunodeficiency virus (type 1)*, burden of.
- HIV DNA extraction from, 317
- HIV expression in, in asymptomatic disease, 324-325

- nonuniform drug resistant quasiespecies in, 394-395
- polymerase chain reaction detection of, 343. See also *In situ polymerase chain reaction*.
- vs. CD4 lymphocytes, 326
- HIV proviral sequences in, 240
- Peripheral neuropathy, in lead poisoning, 650-651
- Peritoneovenous shunt surgery, coagulopathies in, 776
- in disseminated intravascular coagulation treatment, 735
- Personnel, for alternate-site testing. See *Alternate-site testing, personnel for; Training*.
- Petechiae, in disseminated intravascular coagulation, 739
- pathophysiology of, 679-680
- Phadebact test, for rapid microbial identification, 187-188
- Phenotypic assays, for HIV drug resistance, 410, 412-413
- Phenprocoumon, therapy with, monitoring of, 837
- Phosphatidylserine liposome APTT, in lupus anticoagulants, 799
- Physician office laboratory testing, definition of, 455-456
- Phytohemagglutinin-simulated mononuclear cells, in HIV-specific cytotoxic T lymphocyte detection, 273
- PITT system, in vitamin K antagonist therapy monitoring, 837
- Placenta, abruption of, disseminated intravascular coagulation in, 731
- lead measurement in, 658
- Plaque, atherosclerotic, in endothelial injury, 679
- Plasma proteins, in hemostasis, 688-699
- coagulation system, 689-692
- complement activation, 695-696
- fibrin, 691-692
- fibrinolytic system, 692-695
- inhibitor systems, 698-699
- kinin generation, 697-698
- modification of, in liver, 769-770
- synthesis of, in liver, 769-770
- thrombin, 691
- Plasmin, action of, 693-695
- in DIC, 737-738
- measurement of, in DIC, 747-748
- Plasmin-alpha-2-plasmin inhibitor complex, measurement of, in DIC, 748
- Plasminogen, action of, 693-694
- deficiency of, in cirrhosis, 772
- inhibitors of, action of, 694
- measurement of, in DIC, 747-748
- Plasminogen activator, action of, 694
- Platelet(s), activation of, 682-685
- aggregation of, collagen-induced, in antiplatelet therapy monitoring, 838-839
- in von Willebrand's disease, 788
- compounds released from, 682
- dysfunction of, in disseminated intravascular coagulation, 737-738, 748-749
- energy requirements of, 681-682
- function of, evaluation of, automated instruments for, 720-722
- in hemostasis, 681-688
- in liver disease, 773
- glycoproteins of, inhibitors of, therapeutic monitoring of, 839
- inhibitors of, 687
- in disseminated intravascular coagulation, 755, 758
- therapy with, monitoring of, 838-839
- interaction among, 685-686
- membrane glycoproteins of, 687-688
- morphology of, 681
- in disseminated intravascular coagulation, 740-741
- proteins of, 682
- transfusion of, in von Willebrand's disease, 791
- von Willebrand factor extracted from, assays on, 786-788
- Platelet count, in disseminated intravascular coagulation, 748-749
- in heparin therapy monitoring, 834-835
- low. See *Thrombocytopenia*.
- normal, 681
- Platelet factors, 682
- measurement of, in disseminated intravascular coagulation, 748-749
- Platelet neutralization procedure, in lupus anticoagulants, 798-799
- Platelet-induced thrombin generation time, in hirudin therapy monitoring, 836
- Plumbism. See *Lead poisoning*.
- Pneumoslide test, for rapid microbial identification, 188
- Point-of-care testing, definition of, 454-455
- Poisoning, lead. See *Lead poisoning*.
- pol* gene and gene product, 204-206, 211
- Policy and procedure manual, for alternate-site testing, 578-582, 598
- maintenance instructions in, 596
- safety policy in, 596-597
- Polycythemia rubra vera, disseminated intravascular coagulation in, 733
- Polymerase chain reaction. See also *In situ polymerase chain reaction; Reverse transcriptase-polymerase chain reaction*.
- in HIV infection, 262-263, 313-333
- accuracy of, 318-319
- acridinium ester probe in, 317
- before seroconversion, 321-323
- carryover safeguards in, 316-317
- coamplification in, 321

- Polymerase chain reaction (*Continued*)  
 false results in, 317-318  
 historical background of, 314-316  
 hot-start method for, 315  
 in diagnosis, 316-319  
 in drug resistance detection, 410-411  
 in infants of HIV-positive mothers, 323  
 in pathogenesis studies, 324-327  
 in research, 324  
 in resolution of indeterminate serology, 323  
 in therapy monitoring, 327-328  
 multiplex method for, 319  
 nested primers in, 315-316, 320  
 Poisson statistics used in, 320  
 practicality of, 318-319  
 quantitation with, 319-321  
 sample preparation for, 317  
 sandwich system of, 317  
 specificity enhancement of, 314-316  
 in rapid microorganism detection, 191
- Polymerase-specific cytotoxic T lymphocytes, in HIV infection, 279, 283
- Potassium measurement, in portable analyzer, 486  
 preanalytical errors in, 545
- PPG StatPal blood gas tester, 487
- Pregnancy, disseminated intravascular coagulation in, 731-732  
 lead poisoning in, 439, 653  
 lupus anticoagulants in, 797
- Prekallikrein, in hemostasis, 697
- Procedure manual, for alternate-site testing, 578-582, 598  
 maintenance instructions in, 596  
 safety policy in, 596-597
- Professional organizations, position on alternate-site testing, 456-457
- Proficiency testing, in alternate-site testing, 482, 484, 595  
 in multihospital system, 503-504  
 survey on, 637-640
- Propionibacterium*, blood culture of, 109
- Prostaglandins, in platelet function, 686-687
- Prostheses, cardiovascular, disseminated intravascular coagulation from, 734-735
- Protamine sulfate test, for fibrinogen degradation products, 802  
 in disseminated intravascular coagulation, 743-744
- Protease inhibitors, in HIV infection, 378-379
- Protein(s), plasma. See *Plasma proteins*.
- Protein C, deficiency of, coumarin necrosis in, 837  
 in cirrhosis, 772  
 in coagulation regulation, 698
- Protein S, in coagulation regulation, 698
- Proteinuria, in disseminated intravascular coagulation, 739
- Proteoglycans, in coagulation regulation, 701-702
- Prothrombin fragments, in coagulation regulation, 699  
 measurement of, in disseminated intravascular coagulation, 745
- Prothrombin time, in cirrhosis, 772  
 in disseminated intravascular coagulation, 742  
 in oral anticoagulation monitoring, 813-815  
 measurement of, automated instruments for, 710-715
- Proton-induced x-ray emission, in lead measurement, 661
- Pseudohypericin, in HIV infection, 372
- Pseudopods, platelet, 683-684
- Pulmonary disease, in HIV infection, cytotoxic T lymphocytes in, 286
- Pulse oximetry, 467
- Purpura, in disseminated intravascular coagulation, 739
- PYR test, for microorganism identification, in blood cultures, 186
- L-Pyrrolidonyl- $\beta$ -naphthylamide reaction, for microorganism identification, in blood cultures, 186
- Q-Probes Study, of College of American Pathologists, 475-480, 482, 484
- Quality assurance, in alternate-site testing, training for, 590-592  
 in bedside testing, 481-485
- Quality control, in alternate-site testing, 539-557, 633, 637  
 CLIA 1988 regulations and, 550-552  
 definition of, 541  
 financial aspects of, 541-542  
 for sophisticated instrumentation, 548-549  
 history of, 546  
 quality control samples in, 549  
 system checks in, 549  
 testing cycle and, 543-550  
   analytical phase of, 546-549  
   post-analytical phase of, 549-550  
   preanalytical phase of, 544-545  
 training for, 590-594  
 validity checks in, 549  
 in lead measurement, 664  
 of coagulation evaluation automated instrumentation, 725-726
- Rabbit brain neutralization test, in lupus anticoagulants, 799

- Radial immunodiffusion assay, for coagulation evaluation, 723-724
- Radioimmunoassay, for coagulation evaluation, 723, 725  
for fibrinopeptides, in disseminated intravascular coagulation, 747
- Radioimmunoprecipitation assay, for HIV antibodies, 258-259
- Radiology, in bone lead assessment, 663
- Receptor interference, in HIV infection, 213
- Regulations, for alternate-site testing, 480, 583-585. See also *Clinical Laboratory Improvement Amendments*.  
local differences in, 585  
personnel requirements in, 575
- Reproductive system, lead poisoning effects on, 653
- Reptilase test, in disseminated intravascular coagulation, 743
- Resistance, to antiretroviral drugs. See *Antiretroviral drugs, HIV resistance to*.
- Respiratory distress, in disseminated intravascular coagulation, 741
- Respiratory therapy, testing in, 627  
perceived performance of, 642  
proficiency, 639  
revenues from, 635
- Restriction fragment length polymorphisms, in von Willebrand's disease, 789-790
- Results reporting, time of, for biosensors, 462-463
- Retained fetus syndrome, disseminated intravascular coagulation in, 731
- Retroviruses. See also *Human immunodeficiency virus (type 1)*.  
genomic organization of, 204-205  
viral latency and, 242-246  
life cycle of, 203-204
- rev* gene and gene product, 205-206, 211, 243  
inhibitors of, in HIV infection, 376
- Reverse transcriptase, cells expressing, cytotoxic T lymphocytes recognizing, 279, 283  
structure of, drug resistance and, 404-407
- Reverse transcriptase-polymerase chain reaction, in HIV infection, 335-349  
clinical applications of, 340-342  
competitive template for, 339-340  
external controls for, 339  
in cells, 342-343  
in plasma, 343-346  
precision of, 337-338  
priming in, 336  
quantitation with, 339-340  
sample handling for, 338-339
- rgp160, in HIV vaccine preparation, 291
- Ribozymes, in HIV infection, 374-375
- Ristocetin co-factor activity, assay for, 782, 785
- Ristocetin-induced platelet aggregation reaction, 788
- RNA, of HIV, antisense, 374  
measurement of, 307-308
- Ro 5-3335 (benzodiazepine), in HIV infection, 375-376
- Ro 31-8959 (protease inhibitor), in HIV infection, 378-379
- Russell viper venom time, dilute, in lupus anticoagulants, 798-799
- Safety, in alternate-site testing, training for, 596-597  
in blood culture processing, 127  
in blood culture sample collection, 61
- Salmonella typhi*, rapid detection of, in blood, 191
- Sandwich technique, in polymerase chain reaction, in HIV detection, 317
- Sarcoma, Kaposi's, interferon alpha for, 379-380
- Satellite laboratory, 571-572
- Schistocytes, in disseminated intravascular coagulation, 740
- Scoring system, for disseminated intravascular coagulation, in diagnosis, 750-752  
in treatment, 758-759
- Semen, HIV in, 341
- Sensors. See *Biosensors*.
- Sepsis, definition of, 2-3
- Septicemia, definition of, 2-3  
disseminated intravascular coagulation in, 732-733  
treatment of, 754
- Septi-Chek system, for blood cultures, 137-138  
in anaerobic bacteremia, 112  
in fungemia, 85-87, 90-91  
in pediatric patients, 23
- Serologic assays, in HIV infection, 257-269  
for anti-HIV antibodies, confirmatory, 261-262  
screening, 258-260  
for neutralizing antibodies, 264-266  
for p24 antigen, 262  
for type 2 virus antibodies, 261-262  
for viral DNA/RNA, 262-263  
for virions, 262-263  
prognostic value of, 263-264
- Serostat tests, for rapid microbial identification, 188-189

- Shunt, peritoneovenous, in disseminated intravascular coagulation treatment, 735  
 installation of, coagulopathies in, 776  
 Sienco instruments, for platelet function evaluation, 721  
 Signal broth displacement blood culture system, 139-140  
 Skin, antisepsis for, in blood culture  
 sample collection, 60-61  
 bacterial culture from, in catheter-related infections, 54  
 necrosis of, from vitamin K antagonists, 837  
 Sodium, determination of, in portable analyzer, 486  
 Sodium amylosulfate, as anticoagulant, in blood cultures, 75  
 Sodium polyanetholsulfonate, as anticoagulant, in blood cultures, 74-75  
 Soft tissue, lead measurement in, 658  
 sample collection for, 660  
 Soil, lead content of, 425-426  
 Sonoclot instrument, for coagulation evaluation, 714  
 Specimens, collection of, for blood culture.  
 See under *Blood cultures*.  
 size of, for biosensor use, 461-462  
 Spectrophotometer, in chromogenic assay, of coagulation, 717  
 Spectroscopy, near-infrared, in blood gas analysis, 467-468  
 Spumaviruses, genomic organization of, 204-205  
 3SR reaction, in HIV detection, 336  
 STA instrument, for coagulation evaluation, 719-720  
 Standard deviation, in quality control, 546-547  
 Staphaurex test, for rapid microbial identification, 189  
*Staphylococcus aureus*, rapid detection of, in blood, 184-185, 188-189  
 Staphyloslide test, for rapid microbial identification, 189  
 Stool, HIV in, 340-341  
 StrepSlide test, for rapid microbial identification, 188  
 Streptex test, for rapid microbial identification, 188  
 Streptococci, vitamin B<sub>6</sub>-dependent, blood culture of, 127  
*Streptococcus pneumoniae*, rapid detection of, in blood, 185-186, 188  
*Streptococcus pyogenes*, rapid detection of, in blood, 186  
 Subcultures, of blood, 76-78  
 in immunocompromised patients, 41  
 Superantigen effect, in HIV infection, T-lymphocyte depletion and, 228  
 Suramin, anticoagulant effect of, 803  
 Surgery, testing during, 627  
 perceived performance of, 642  
 personnel for, 632  
 proficiency, 638  
 revenues from, 635  
 Susceptibility testing, antibiotic, 171-179  
 Sweat, HIV in, 341  
 Syncytia formation, by T lymphocytes, in HIV infection, 232, 304-305, 408  
 Systemic lupus erythematosus, lupus anticoagulants in, 797-798  
 T lymphocytes, CD4, analogs of,  
 antiretroviral activity of, 370-371  
 HeLa cell plaque reduction assay, in HIV drug resistance monitoring, 413  
 HIV infection impact on, 205, 207-208, 221-238  
 anergy, 229  
 antiretroviral drugs affecting, 370-371  
 apoptosis, 229-230  
 direct cytopathy, 225  
 endocytosis, 213-214  
 immunomodulation, 225-228  
 in active disease, 231-232  
 in acute disease, 221-223  
 in quiescent disease, 223, 225-228  
 kinetics of depletion, 232-234  
 mechanisms of, 222  
 Nef protein and, 212-214  
 polymerase chain reaction studies of, 324-325, 342-343  
 precursor cell loss, 230-231  
 signaling defects, 228-230  
 superantigen effects, 228  
 syncytia formation, 232, 304-305, 408  
 time course of, 222  
 virus burden in, 302-305  
 recombinant soluble forms of,  
 antiretroviral activity of, 370-371  
 CD8, HIV infection impact on, 223  
 cytotoxic, in HIV infection, 271-299  
 activity decline in, 289  
 cloned, 273-274, 290  
 cytotoxicity assay of, 277  
 detection of, 272-277  
 envelope-specific, 283-284  
 epitopes recognized by, 277-285  
 functions of, 285-290  
 gag-specific, 278-279  
 in pediatric patients, 285-286  
 nef-specific, 284-285  
 pathogenetic role of, 286-287  
 polymerase-specific, 279, 283

- protective role of, 285-286
- target cell recognition in, 274-277
- vaccine-induced, 290-292
- viral escape from, 287-290
- TAR elements, of HIV gene, 208, 210
- in gene therapy, 381
- Target cells, for cytotoxic T-lymphocyte detection, 274-277
- TAS Analyzer, for coagulation evaluation, 715
- tat* gene and gene product, 205-206, 211, 243
  - inhibitors of, in HIV infection, 375-376
- Teeth, lead measurement in, 657, 660
- Telangiectasia, hereditary hemorrhagic, disseminated intravascular coagulation in, 734
- Temperature, for blood culture incubation, 73-74
- Template bleeding time, in von Willebrand's disease, 789
- Terminal subcultures, of blood, 76-78
  - in immunocompromised patients, 41
- Thermocyclase test, for microorganism identification, in blood cultures, 185
- Thrombin, action of, in disseminated intravascular coagulation, 738
  - formation of, 691
  - inhibitors of, therapy with, monitoring of, 835-836
  - measurement of, chromogenic assay in, 716-717
- Thrombin time, in disseminated intravascular coagulation, 743
  - in heparin therapy monitoring, 827, 829
- Thrombin-antithrombin complex, measurement of, in disseminated intravascular coagulation, 745
- Thrombin-inhibiting peptides, therapy with, monitoring of, 836
- Thrombocytopenia, from lupus
  - anticoagulants, 798
  - heparin-induced, 834-835
  - in disseminated intravascular coagulation, 735, 737-738, 740, 748-749
  - in liver disease, 771, 773
  - in von Willebrand's disease, 788
- Thromboelastograph, for coagulation evaluation, 714
- Thromboplastin, standardized preparations of, for oral anticoagulation monitoring, 814-817
- Thromboplastin time, in vitamin K antagonist therapy monitoring, 837
- Thrombosis, from lupus anticoagulants, 797-798
  - in cardiovascular prostheses, 735
  - in disseminated intravascular coagulation, 730, 738
  - in diagnosis, 739
  - morbidity and mortality from, 741-742
  - morphology of, 740-741
  - treatment of, 754-755
  - of hepatic artery, in liver transplantation, 776
- Thromboxane(s), in platelet function, 686-687
- Thromboxane receptor antagonists, therapy with, monitoring of, 839
- Thromboxane synthetase inhibitors, therapy with, monitoring of, 839
- Tiacytidine (3TC), HIV resistance to, 396, 398
  - biochemical bases of, 406
- TIBO compounds, HIV resistance to, 397, 399
- Ticlopidine therapy, monitoring of, 838-839
- Tissue thromboplastin inhibition test, in lupus anticoagulants, 799
- Topoisomerase inhibitors, in HIV infection, 372
- Toxins, conjugated to CD4 cells, antiretroviral activity of, 371
- Training, for alternate-site testing, 482, 578-582, 588-590
  - aids for, 597-598
  - concepts of, 598-599
  - continuing education in, 599-602
  - director for, 582
  - elements of, 601-602
  - ethos in, 589
  - in patient-centered units, 526, 528-529, 535-536
  - instrument maintenance, 595-596
  - laboratory principles, 590-599
  - quality assurance, 590-592
  - quality control, 592-594
  - safety principles, 596-597
- Tranexamic acid, in disseminated intravascular coagulation, 757
- Transcription-based amplification system, in HIV detection, 336-337
- Transcutaneous biosensors, 466-467
- Transdominant mutant proteins, expression of, in gene therapy for HIV infection, 381
- Transducer, in biosensor, 460-461
- Transfusion therapy, in disseminated intravascular coagulation, 756
- Transplantation, immunosuppression in, blood-borne infection in, 32-33
  - liver, coagulopathies in, 774-776
- Triage device, for urine screening, 487
- TSAO compounds, HIV resistance to, 397, 399
- Tuberculosis, disseminated. See *Mycobacteremia*.
- Tumor necrosis factor, from cytotoxic T lymphocytes, in HIV infection pathogenesis, 287

- Universal precautions, in blood culture sample collection, 61
- Untranslated binding protein, in HIV gene transcription, 245
- Upstream suppressor sequence, of HIV gene, 245
- Uracil N-glycosylase, in polymerase chain reaction, in HIV detection, 316
- Urea determination, in portable analyzer, 486
- Urine, drug screening of, portable device for, 487
  - lead measurement in, 656
  - methods for, 662
  - sample collection for, 659-660
- Vaccines, for HIV infection, cytotoxic T lymphocytes induced by, 290-292
- Vacutainer system, for blood cultures, 138
- Varicella, disseminated intravascular coagulation in, 733
- Varices, esophageal, embolization of, coagulopathies in, 776-777
- Vascular system, endothelium of, in hemostasis, 678-680
  - injury of, disseminated intravascular coagulation in, 735
  - fragility of, petechiae in, 679-680
  - function of, in hemostasis, 678-680
  - morphology of, 678
  - permeability of, petechiae in, 679
- Vasoconstriction, regulation of, 680
- Vasospastic disease, disseminated intravascular coagulation in, 734
- Venipuncture, in blood culture sampling, vs. catheter specimens, 61-62
- Veterans Affairs medical care system, alternate-site testing in. *See Alternate-site testing, consolidation in multihospital systems.*
- vif gene and gene product, 205-206, 211, 214-215
- Viral cultures, blood, in immunocompromised patients, 39-40
  - in HIV drug resistance monitoring, 412-413
- Viral infections, disseminated intravascular coagulation in, 733
- Viremia, in HIV infection, vs. disease progression, 303-304
- Vitamin B<sub>6</sub>-dependent streptococci, blood culture of, 127
- Vitamin D metabolism, lead poisoning and, 438
- Vitamin K, antagonists of, side effects of, 837
  - therapy with, monitoring of, 837
  - deficiency of, in liver disease, coagulopathies in, 773-774
  - in coagulation, 691
  - requirements of, in coagulation protein modification, 769-770
- Vitek system, for antibiotic susceptibility testing, 176
  - for rapid microbial identification, 186-187
- von Willebrand factor, antigen of, assay for, 782, 785-786
  - assays for, 782, 785-788
  - deficiency of, 783
  - levels of, factors affecting, 784-785
  - multimers of, assay for, 782, 786
  - structures of, 784
  - qualitative abnormalities of, 783-784
  - replacement of, in von Willebrand's disease, 791
  - structure of, 784
- von Willebrand's disease, 781-794
  - acquired, diagnosis of, 790-791
  - laboratory assessment of, 808
  - assays in, 782, 785-788
  - classification of, 783-784
  - clinical presentation of, 782-783
  - definitions in, 782
  - diagnosis of, acquired, 790-791
  - problems in, 791
  - genetic studies in, 789-790
  - laboratory tests for, 784-789
  - nomenclature in, 782
  - platelet-type, 788
  - prenatal diagnosis of, 790
  - prevalence of, 781
  - treatment of, 791
  - undiagnosed, 781
  - variants of, diagnostic problems with, 791
- vpr gene and gene product, 205-206, 211, 215
- vpu gene and gene product, 205-206, 211, 215-216
- vpx gene, 205-206
- Waived test category, regulations on, 551, 583-584
- Warfarin therapy, monitoring of, 837. *See also Oral anticoagulation, monitoring of.*
- Water, drinking, lead content of, 426-427
- Western blot test, in HIV infection, 261-262
  - indeterminate, polymerase chain reaction resolution of, 323
- White clot syndrome, in heparin therapy, 834-835
- Whole blood clotting time, in heparin therapy monitoring, 827
- Wide area network, for laboratory information communication, 565-566



World Health Organization, in oral anticoagulation monitoring standardization, 814-821

X-ray fluorescence technique, in lead measurement, 662-663

Zalcitabine (ddC), HIV resistance to, 396, 398-399

biochemical bases of, 406-407  
in combination therapy, 400

Zidovudine (AZT), HIV resistance to, as pathogenic factor, 408-409

biochemical bases of, 404, 406-407

crossresistance of, 398

genetic factors in, 395-396, 398

in combination therapy, 400-404

laboratory monitoring of, 410-413

polymerase chain reaction studies of, 324

in HIV infection, efficacy of, monitoring of, 413-414

interferon alpha with, 379-380

monitoring of, polymerase chain reaction in, 327, 345-346

virus burden response to, 305-308

with *N*-butyl deoxynojiriminic, 377

Zinc protoporphyrin, measurement of, 661-662

vs. free erythrocyte protoporphyrin, 654